CILOXAN Eye Drops contains
ciprofloxacin hydrochloride equivalent to 3 mg/mL ciprofloxacin, preserved with benzalkonium chloride 0.006% (m/v).
CILOXAN Eye Ointment contains ciprofloxacin hydrochloride equivalent to 3 mg/g ciprofloxacin in an anhydrous ophthalmic ointment base. It does not contain a preservative.

Pharmacodynamic properties
Ciprofloxacin is a broad-spectrum water-soluble fluoroquinolone antibacterial. It has cidal and inhibitory activities against bacteria, which result from an interference with the DNA gyrase, an enzyme required by the bacterium for the synthesis of DNA. Thus, the vital information from the bacterial chromosomes cannot be transcribed any longer, which causes a breakdown in the bacterial metabolism. Ciprofloxacin has anin vitro activity against a wide range of Gram-negative microorganisms including Pseudomonas aeruginosa and Serratia marcescensand Gram-positive bacteria, such as staphylococciand streptococci includingStaphylococcus aureus (including methicillin-susceptible strains), Staphylococcus epidermidis, Streptococcus pneumoniae and Streptococcus (viridans group). Sensitivity of methicillin resistant Staphylococcus aureus is variable.
Pharmacokinetic properties
Ciprofloxacin is absorbed systemically after topical ocular administration. The maximum reported plasma concentration of ciprofloxacin was less than 5 ng/mL (some 450-fold less than levels observed following simple 250 mg oral administration)and the mean plasma concentration was less than 2.5 ng/mL.

CILOXAN Eye Drops and Eye Ointment are indicated for the treatment of corneal ulceration and conjunctivitis caused by susceptible strains of bacteria.
Appropriate monitoring of bacterial response to topical antibacterial therapy should accompany the use of CILOXAN Eye Drops and Eye Ointment.

Hypersensitivity to ciprofloxacin or any component of this medication. Hypersensitivity to other quinolones may also contra-indicate the use of ciprofloxacin.